Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. [PDF]
Masson W +4 more
europepmc +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions. [PDF]
Kuang J, Hao L, Zhang M, Yang Z.
europepmc +1 more source
Substrate selectivity by proprotein convertases
Nelsen, Sylvia M., Christian, Jan L.
openaire +1 more source
The Proprotein Convertase SKI-1/S1P [PDF]
Antonella Pasquato +9 more
openaire +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 Induces Platelet-Derived Transforming Growth Factor-<i>β</i> to Promote Myocardial Fibrosis After Myocardial Infarction. [PDF]
Wang Q, Huang W, Xia D, Wang F, Nair S.
europepmc +1 more source
Genetic Pathogenesis of Abdominal Aortic Aneurysm and the Role of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9). [PDF]
Choi JY, Gwon JG.
europepmc +1 more source
Directional and balancing selection on proprotein convertase subtilisin/kexin type 6 (PCSK6) [PDF]
Sonja Kuderer +2 more
openalex +1 more source
Structural insights into proprotein convertase activation facilitate the engineering of highly specific furin inhibitors. [PDF]
Klaushofer R +7 more
europepmc +1 more source

